nDatalyze (CSE: NDAT) (OTCQB: NDATF) is focused on developing technologically based, specialized products, databases and applications. Based in Calgary, the company currently has three divisions: the YMI division that develops a data-driven consumer mHealth application designed to predict current and future health conditions in an effort to lessen the cost of health services as well as decrease the load on health care services, its MLdelic division which focuses on providing a database platform that may be used to predict potential benefits associated with the use of entheogenic compounds within the mental health sector, and Medxtractor with installations of its small-scale bio-extractors worldwide. For more information, visit the company’s website at https://ndatalyze.com/ or view/download a Factsheet at https://www.ndatalyze.com/factsheet/ Contact: James Durward, President tel/text: (403) 689-3901 Email: JimD@ndatalyze.com About InvestorBrandNetwork’s Virtual Coverage The InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company, is provides the online investment community with custom-built portals that include summaries on hundreds of presenting companies. In addition to enabling proficient evaluation of each company via one-click access to market research tools and helpful website links, IBN utilizes social media and syndicated articles to maximize the visibility of various investor conferences. For more than a decade, IBN has provided real-time coverage for numerous global events and conferences through its various brands, social media accounts and investment newsletters. To further expand visibility of participating companies at these events, and to ensure another successful year for its event collaborations, IBN’s syndication partners have extended digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer InvestorBrandNetwork (IBN) Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

• Mydecine recently reported a positive Pre-IND meeting with the FDA for the MYCO-001 smoking cessation study
• According to the Center for Disease Control (“CDC”), tobacco is the leading cause of preventable deaths in the U.S.
• Following the FDA meeting, the company now intends to perform a Phase 2b study and then a Phase 3 study instead of a seamless Phase 2/3 clinical trial
• Mydecine plans to submit a request for breakthrough therapy status with its IND submission

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) has continually taken steps toward fulfilling its mission to become a trusted source of safe and effective medication-based treatments for mental health and addiction disorders by developing drug candidates, partnering to advance research, and more. Under the stewardship of Dr. Matthew W. Johnson, Ph.D., a Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins University (“JHU”) contracted last September (https://ibn.fm/SnsIY), for example, Mydecine plans to conduct a placebo-controlled study evaluating the science and efficacy of MYCO-001, its lead psilocybin-based drug candidate, in treating nicotine dependence, subject to the fulfillment of certain conditions, including a Pre-Investigational New Drug (“IND”) meeting with the Federal Drug Administration (“FDA”) as well as successful IND and breakthrough therapy status submissions. Most recently, Mydecine reported a positive Pre-IND meeting held on February 28 (https://ibn.fm/Ze5ci). Following this meeting, the company has decided to undertake a Phase 2B study and then a Phase 3 study instead of the initial approach wherein it intended to conduct the study as part of a seamless Phase 2/3 clinical trial. The company’s new approach of separating the trials enables them to publish data after each study rather than waiting until both phases are complete. “We had an extremely positive meeting with the FDA in regards to our proposed smoking cessation study. The FDA provided helpful feedback on our study design that we will implement,” commented Mydecine CEO Josh Bartch in a March 1 news release. “We are now working rapidly in preparing our IND submission of the 2B portion of the study, which we believe will be next month. Once cleared, we will move swiftly into patient recruitment.” In addition to the positive feedback, Mydecine also highlighted its plans to submit a request for breakthrough therapy designation with its IND submission. According to the company, psilocybin-assisted treatment has shown marked advantages over available therapies for tobacco addiction, including a substantial increase in safety and efficacy. Data from JHU’s ongoing studies, in fact, show that psilocybin-assisted treatments are 2-3 times more effective in treating nicotine addiction than existing treatments. With the Center for Disease Control (“CDC”) stating that tobacco use is the leading cause of preventable death in the United States (https://ibn.fm/t2lwh), a breakthrough designation could go a long way in remedying the situation. Equally, Mydecine’s Phase 2B and Phase 3 trials could provide the data needed to support this goal. According to Bartch, Mydecine has worked on the proposed smoking cessation study over the last two years and has even partnered to move its R&D forward. For instance, last August, Mydecine signed a five-year master collaboration research agreement with the JHU School of Medicine. Under the terms of the partnership, Dr. Johnson would spearhead research on the therapeutic use of psychedelics. This agreement would allow JHU and Mydecine to further advance research on novel psychedelic-based therapies for mental health conditions and addiction disorders (https://ibn.fm/UUpvC). Mydecine announced MYCO-001, composed of 99% pure psilocybin, early last year. The company intends to administer MYCO-001 as a possible treatment for post-traumatic stress disorder (“PTSD”) as well as nicotine addiction and is, in fact, the only biotech company targeting smoking cessation as an indication. Its planned clinical trials will build off Dr. Johnson’s ongoing research, which has evidenced an 80% efficacy rate at six months (https://ibn.fm/dIsLY). For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• In 2021, energy production accounted for 60% of total greenhouse gas emissions globally
• Ammonia and hydrogen have been deemed as the two promising solutions for clean energy sources
• FuelPositive, through its green ammonia production technology, offers a means to store hydrogen as green ammonia for easier transportation and storage
• Through this technology, FuelPositive addresses the shortcomings of hydrogen as an energy source compared with green ammonia, ultimately stamping its position as a leader in clean energy solutions

Energy has been regarded as the dominant contributor to climate change. As of 2021, it accounted for about 60% of total greenhouse gas emissions, including CO2, which has increased by over 46% since 1990 (https://ibn.fm/1ltp3). There is a growing need to shift to renewable energy sources and adopt clean energy solutions. Collectively, countries are aiming for universal access to modern, affordable, and reliable energy services by 2030. They are also targeting a substantial increase in the share of renewable energy in the global energy mix (https://ibn.fm/CVP90). One candidate showing great promise, not just as an energy source but also as an energy storage solution, is green ammonia. In a study published by the Oxford Institute for Energy Studies, ammonia and hydrogen were deemed the two most promising solutions among the currently available energy storage options and techniques. Some of the aspects evaluated in the study included the economic efficiency of ammonia and its ability to address challenges including, but not limited to, transportation, decarbonization of energy systems, and scalability (https://ibn.fm/2h4tR). FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF) is focused on the licensing, partnership, and acquisition opportunities associated with clean energy solutions. With its flagship product – a decentralized green ammonia production system, the company is solving issues formerly related to hydrogen as an energy source. Because green ammonia contains hydrogen, it provides the benefits of pure hydrogen, but does not have the problems associated with pure hydrogen. FuelPositive’s technology offers a means to transport and store hydrogen as green ammonia, with the option of easy conversion back to hydrogen that can then be used in hydrogen fuel cells and other pure hydrogen applications. “Think of ammonia as the perfect carrier for hydrogen, and if the end-use requirement for pure hydrogen, then the safest and most practical way to get that hydrogen where it needs to be is inside of FuelPositive’s green ammonia,” said Ian Clifford, FuelPositive CEO. However, FuelPositive makes the case that ammonia is a more practical option for fuel, energy storage, fuel cells and most other applications being considered for pure hydrogen. Not only does the production of its green ammonia require less energy than producing hydrogen on its own, but it stores 65% more hydrogen than highly compressed pure hydrogen. This puts FuelPositive at the forefront of clean energy solutions. What the company is doing and what it has achieved so far prove that green ammonia is a viable, clean energy alternative. FuelPositive is setting the stage and the standard for clean energy solutions globally. Its research and innovation bring society closer to universal access to modern, affordable, and reliable energy services by 2030. For more information, visit the company’s website at www.FuelPositive.com. NOTE TO INVESTORS: The latest news and updates relating to NHHHF are available in the company’s newsroom at https://ibn.fm/NHHHF

• EIA projects that crude oil prices will remain high enough to drive U.S. crude oil production to record-high levels in 2023
• The agency observed that crude oil prices have generally increased since April 2020
• Laredo has historically leased 23,739 mineral acres in the Western Williston Basin of Montana
• The company recently purchased 2,361 additional mineral acres, bringing the total Montana leased acres to 26,100

The U.S. Energy Information Agency (“EIA”) is looking for domestic crude oil production to reach record-high levels in the next two years, according to its February 2022 Short-Term Energy Outlook (https://ibn.fm/ZKHa3). Oil and gas exploration and production company Laredo Oil (OTC: LRDC), is in a strong position to benefit from that projected growth as it focuses on acquiring, developing and operating undervalued conventional oil and gas properties in the United States. “In our February 2022 Short-Term Energy Outlook (‘STEO’), we forecast that crude oil prices will remain high enough to drive U.S. crude oil production to record-high levels in 2023, reaching a forecast 12.6 million barrels per day (b/d),” the EIA reported. “In the February STEO, we forecast that U.S. crude oil production will increase to 12.0 million b/d in 2022, up 760,000 b/d from 2021. We forecast that crude oil production in the United States will rise by 630,000 b/d in 2023 to average 12.6 million b/d. We expect more than 80% of that crude oil production growth to come from the Lower 48 states (L48), which does not include production from Alaska and the Federal Offshore Gulf of Mexico.” The agency noted that legacy production, or crude oil production from existing wells, usually decreases rather quickly in tight oil formations, but the agency anticipates that production from new wells will offset these legacy production declines. In addition, EIA observed that crude oil prices have generally increased since April 2020, resulting in increased crude oil production. Laredo is looking to contribute to increased oil production. The company’s strategy involves a focus on unlocking value where others have overlooked it, emphasizing free cash flow that allows the company to seize opportunities quickly and taking a disciplined approach by de-risking projects and exercising care in incurring expenses and allocating capital (https://ibn.fm/D7NHQ). Following this strategy, Laredo has leased 26,100 mineral acres in the Western Williston Basin of Montana; those leases were obtained at favorable prices during the most recent down cycle. Laredo continues to look for undervalued opportunities in the area. The company plans to drill the first development well at one of the first of 10 potential locations it has identified in the coming months, and if that well yields the anticipated results, the company will begin drilling additional wells in the area as soon as practical. The company believes the leased acreage has the potential to yield at least five years of development opportunities. Based in Texas, Laredo Oil is a publicly traded oil and gas exploration and production company. Specializing in conventional and enhanced oil recovery techniques, the company is engaged in the acquisition and development of both undervalued quality conventional oil and gas properties and select mature oil fields. In addition to pursuing conventional recovery methods in target locations, Laredo Oil intends to utilize its proprietary Underground Gravity Drainage(TM) model, where conditions warrant, to profitably recover stranded oil reserves previously thought to be incapable of economic recovery. For more information, visit the company’s website at www.Laredo-Oil.com. NOTE TO INVESTORS: The latest news and updates relating to LRDC are available in the company’s newsroom at https://ibn.fm/LRDC

• The growing popularity of artificial intelligence-enhanced security devices and big data collection are causing a growing revolution in security technology
• Analysts at Research and Markets forecast growth in the global surveillance video market through 2026 at a CAGR of 10.2 percent in response to the evolving technological demands on the sector
• Autonomous security robot developer Knightscope recently went public on the Nasdaq Global Market with its array of models that use advanced technology to patrol and monitor client properties on a 24/7 basis – without human intervention
• A key component of the Knightscope robots’ operational capabilities is the Knightscope Security Operations Center (“KSOC”) that relays data and live-streams 360-degree eye-level video to authorized security professionals

The importance of the security industry’s evolution via the use of artificial intelligence (“AI”) and software analytics is evident in the sector’s market growth. A variety of solutions incorporating technological advances, driven by users’ growing demand for big data and AI functionality, are ushering in a new era of physical security solutions (https://ibn.fm/9XvkG). The rising use of thermal cameras, Internet of Things (“IoT”), and smart city devices, are creating a growing list of opportunities that lead analysts at Research and Markets to predict a CAGR of 10.2 percent for the global surveillance video market between 2021 and 2026, achieving nearly $70 billion in revenues (https://ibn.fm/9aeVK). Autonomous security robot (“ASR”) developer Knightscope (NASDAQ: KSCP) is considered a leading player in intelligent security solutions, employing a variety of stationary and mobile robots to surveil clients’ properties, anticipating potential threats to the clients’ operations, whether in the form of possible crime hazards to personnel or object hazards that may prove destructive to facilities — relaying an array of data back to the security team. While the security robots perform many functions autonomously, the key of the Knightscope technology is the Knightscope Security Operations Center (“KSOC”). This fully functional browser-based user interface provides the managers simple access to real-time data whenever it’s needed to view and interact with the ASRs’ 24/7 flow of data stemming from facial recognition, thermal scans, automatic license plate recognition, video of people’s ingress to select areas, and more (https://ibn.fm/nZYKK). Knightscope’s blog provides a potential scenario in which a general manager can start each workday with a feeling of security. For example, parking areas patrolled by ASRs are no longer occupied by people sleeping in cars or stairwells, and vehicle break-ins have been stopped. Operators can later tap into ASR video feeds to observe that employees are working safely and effectively, while perhaps being warned that a delivery driver is in an unauthorized area. The robot may then patrol a perimeter area and provide reports on its integrity (https://ibn.fm/YSSpL). The scenario anticipates a number of benefits for the company, including increased employee safety and satisfaction that has resulted in fewer costs from worker compensation and wrongful termination lawsuits, fewer costs associated with training new or temporary personnel, fewer costs associated with vandalism or other types of property destruction, and fewer losses to theft. “Robots are deployed to do the monotonous, computational heavy work while the strategic, hands-on activities are the responsibility of the humans,” Knightscope Chairman and CEO William Santana Li stated in a recent news release announcing a strategic partnership with global security and facility services company Allied Universal(TM) (https://ibn.fm/YAUeZ). Huntington Park, California Chief of Police Cosme Lozano successfully encouraged the city council to extend the municipality’s contract with Knightscope last year, stating a robot patrolling a park of concern is “not intended to eliminate or reduce the work of human police officers. It’s simply to enhance our ability to deliver police services. You can think of it if you will as a patrol vehicle, meaning that the patrol vehicle creates that presence and that extension of the police department” (https://ibn.fm/H7S64 – see 20 minute mark). For more information about Knightscope (NASDAQ: KSCP), visit the company’s website at www.Knightscope.com and if you have a need for subscription service you may request a private demonstration of the technology at www.Knightscope.com/demo. NOTE TO INVESTORS: The latest news and updates relating to KSCP are available in the company’s newsroom at https://ibn.fm/KSCP

• Red White & Bloom Brands is a cannabis and hemp multi-state operator, focused on product consistency and quality, critical to the developing cannabis market that is rapidly growing state by state
• The company’s successes in Michigan, a leading U.S. cannabis market, include the acquisition of full licensing, a 15,000-square-foot manufacturing and distribution facility, and more than 20 new potential locations for cultivation and dispensaries
• In Florida, RWB is building on its acquisition of a 45,000-square-foot cultivation facility to provide premium inventory to several existing dispensaries and new sites expected to open during this year’s Q1

Mainstream wellness consumers have cast sidelong glances at the explosion of cannabidiol (“CBD”) brands over the years, particularly those that require inhalation. But increasing regulatory approval on a state-by-state basis, as well as the 2,000-plus CBD brands that range from easy access “gas station” products to “premium” boutique shop inventory, evidence that the consumer appeal of medicinal cannabis is still showing a significant expansion curve. “While an increasing number of wellness product manufacturers are toying with incorporating CBD and other cannabinoids into products, their efforts have been stymied by the very nature of the ingredients,” Tennessee-based Volunteer Botanicals CEO Derek Odette recently told lifestyle brand Nutritional Outlook (https://ibn.fm/3ABgW). “When cannabinoids and terpenes are extracted from the hemp or marijuana plant, the result is an oil in the same way perfume and cooking oils are extracted from organic materials. Unfortunately, oil-based cannabinoids don’t play well with many nutraceutical ingredients. It can be extremely difficult to balance ratios between different ingredients, which ultimately leads to inconsistent products.” Premium cannabis brand multistate operator Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) has been building assets steadily in Michigan, Florida, Illinois, Massachusetts, and Arizona, while working to establish the quality and consistency wellness consumers seek. After struggling with market perceptions of its business plan at the close of the year, Red White & Bloom announced full licensing for manufacturing both medical and adult use cannabis products in Michigan in January, along with closing a lease assignment for a 15,000-square-foot manufacturing, processing and distribution facility in the city of Warren. “This Warren facility allows us to centralize distribution for our ‘house of premium brands’ in Michigan and finally report all of our Platinum Vape(TM) wholesale sales on a much less confusing and straightforward basis,” CEO and Chairman Brad Rogers stated (https://ibn.fm/wGltC). The manufacturing facility is a key part of RWB’s acquisition strategy for 18 Michigan dispensaries, four cultivation facilities and other important real estate. The company also is using its acquisition of a 45,000-square-foot Florida cultivation facility to spearhead premium inventory production for several existing and new dispensaries under the company’s banner. “The Apopka facility will deliver the cultivation needed to meet our significant retail expansion goals throughout the state. It will also allow us to serve patients with the quality and consistency they deserve,” Rogers stated last fall (https://ibn.fm/er8HJ). “Despite being relatively new players in the Florida market, I feel we have the most talented team of PhDs and horticulturalists, and an incredible grow infrastructure to bring the highest quality products, rich in terpenes and cannabinoid content, to some of the best retail locations in the state starting in Q1 2022,” he added in October. Michigan positioned itself as a leading market in the United States for cannabis sales with $1.79 billion transacted last year. Red White & Bloom’s seed-to-sale integration for the medical and adult use sectors was further enhanced last month when it closed its acquisition of PharmaCo, Inc., granting the company over 20 assets in the state for potential new cultivation and dispensary locations (https://ibn.fm/EbmrU). For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• InnerScope Hearing Technologies has emerged as a leading player in the hearing aid market, including being Walmart’s largest supplier, as part of its large distribution network
• The company has recently launched a new call center free to customers and provides comprehensive services from initial inquiry through lifetime product care
• Management expects the new call center and sales team combined with expansive sales domain to lead to “explosive growth” over the coming 6-12 months

There has been explosive growth in the direct-to-consumer (“DTC”) market, where companies are able to improve margins by eliminating intermediaries and focusing on promoting and selling products straight from the manufacturer to the intended consumer. Thanks to technological advancements, the business strategy has swept across virtually all industries, with innovators like InnerScope Hearing Technologies (OTC: INND) making cutting-edge hearing aids available to people without the need to leave the comfort of their homes. From its headquarters in Roseville, California, InnerScope is emerged as a leading DTC manufacturer and distributor of FDA-registered hearing aids, hearing assistive devices, hearing health-related products, and Personal Sound Amplifier Products (“PSAPs”) dedicated to addressing the global demand for affordable hearing solutions. Simply, the company has broken down barriers that have historically kept millions of people with hearing deficits from utilizing an array of hearing products to improve their quality of life. InnerScope has been building a vertically integrated business model and extensive distribution network that offers its products through major traditional brick-and-mortar retail stores and popular specialized online platforms. The upstart company earned a top spot at Walmart, now the retail juggernaut’s largest hearing aid supplier with displays in 750+ stores in the U.S., in addition to selling through Cardinal Health’s RGH Enterprises and retailers, including Hy-Vee, Giant Eagle, Hartig Drug, Food City and more. In the digital space, InnerScope runs its own online shop at MyHearIQ.com, sells on Amazon.com, and has partnered with FSAstore.com, HSAstore.com, and WellDeservedHealth.com, eCommerce sites catering to consumers enrolled in flexible spending accounts (“FSA”), health saving accounts (“HSA”), and employers’ health incentive programs. Recently, InnerScope widened its services with the launch of its own internal customer call center for the approximately half a million customers of its subsidiary HearingAssist and its iHear hearing aid customers. The launch of the call center (available at 1-800-700-4327) dovetails with the launch of the new HearingAssist.com website. Quality is a hallmark of the InnerScope ecosystem, and the company completed an exhaustive recruitment process to staff its new call center. The new hires are comprised of licensed hearing professionals, doctors of audiology, seasoned customer care specialists, and veteran salespeople, many of which were previously with InnerScope competitors such as Eargo, Hear.com, and YesHearing.com. The bespoke call center is designed for scalability, initially consisting of 15 staffers, with new team members being added each month, according to InnerScope President and CEO Matthew Moore. InnerScope is providing a spate of services free of charge through the call center to ensure the ultimate customer experience beginning with product specialists spending time explaining the different features and benefits of models and products that will best suit the customer’s needs ahead of making a purchase. The suite of services also makes free consultations available with InnerScope’s licensed hearing professionals. These hearing professionals will help customers better understand their hearing issues and assist in proper fittings to maximum benefits. Following the sale, the call center includes After-Care Service Representatives to assist with any questions or concerns throughout the product’s lifetime. “Our new Call Center will allow InnerScope to assume more ownership of the way we approach and deliver a personalized high-touch experience for the customer,” said Moore in a press release on the developments. He concluded, “Our call center is part of our commitment to building industry-leading hearing aid brands backed by superior hi-touch customer service. With our continued product innovation and our ever-growing wholesale/retail partners, including Walmart, we believe there is a tremendous market opportunity for InnerScope to experience explosive growth potential over the next 6 to 12 months.” For more information, visit the company’s website at www.INND.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• Friendable’s Fan Pass Live artist platform and music distribution acquisition, Artist Republik, have achieved the first milestones for integration
• The next phase of growth will include Friendable’s entry into the Metaverse and NFTs
• The global NFT market size reached $50.10 billion in 2021 and is expected to reach $130.35 billion by 2028

Friendable (OTC: FDBL), a mobile technology and marketing company, has announced that phase one of the Fan Pass Live artist platform and Artist Republik integration has been completed. In light of these significant milestones, Friendable has now positioned itself as a full circle offering as the only 360, all-inclusive music artist platform for those artists who wish to maintain control of their art while having access to a support system for development, launches, and monetizing their career. Now, Friendable’s offering includes everything from music development, access to a custom list of curators, and tools to help grow an artist’s fanbase – through livestream, virtual events, ticket sales, and merch development.

One way artists on the platform can generate revenue and attract a wider fanbase is through Fan Pass Live’s monthly contests, with the March edition rewarding the highest number of streams through the Fan Pass app. The top three artists with the highest number of streams during March will win:

• First Place: Choice of any three Artist Pro Services
• Second Place: Choice of any two Artist Pro Services
• Third Place: Choice of one Artist Pro Service
• Bonus: When artists promote three of their streams and tag Fan Pass on Instagram, they will receive a free $10 Grow With Us campaign to add listeners to grow their Spotify or SoundCloud.

Fan Pass Live offers its members exclusive Artist Pro Services that include three categories with three tiers – Artist/Band Logo Design (Basic, Standard, Custom/High Resolution), Merch Design (Basic, Standard, Pro), and Marketing Materials (Basic, Standard, Premium). Grow With Us is available through Artist Republik. It allows artists to market music and accelerates their music careers. Grow With Us is a way to increase engagement on Spotify and SoundCloud by advertising tracks, channels, and playlists through an expansive network.

On the heels of these new milestones being achieved, Friendable is also setting its sights on Metaverse and NFT (non-fungible token) opportunities for both artists and fans. The industry has seen an increased interest in successful crypto integrations that will allow artists to earn more in “days” than they have earned in years – in some cases. Reflecting this growing interest, the global NFT market size reached $50.10 billion in 2021 and is expected to grow at a CAGR of 10.7% during the forecast period of 2021 through 2028. By 2028, experts expect that revenue will reach $130.35 billion (https://ibn.fm/C62rZ).

“Our team’s ability to complete the phase one integration and business combination has been truly amazing. There is always a learning curve when adding anything to an existing business model, and having an existing artist community to introduce new support and services to has to be handled incrementally as well,” Friendable CEO Robert A. Rositano Jr. said (https://ibn.fm/JImsF).

He underlined that the Fan Pass Live team has begun introducing all the additional service offerings that have the independent artist community buzzing about Friendable’s 360 offering or anti-record label solution to build their careers while maintaining control. “Additionally, we are now prepared to turn attention to our next offering expansion with a focus on identifying Metaverse and NFT strategies that can propel our model forward. Partnerships, exclusives, and acquisitions are also part of this strategy,” Rositano Jr. explained.

For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com.

NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Lexaria’s patented DehydraTECH technology proved effective for sildenafil delivery in animal study PDE5-A21-1
• The company also made some notable strides with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD
• By doing so, it hopes to capitalize on the growing cardiovascular drugs market, which is projected to be valued at $107.8 billion by 2025 (https://ibn.fm/LwAUc)
• With the success of its studies thus far, the company seeks to conduct even more trials over the 2022 calendar year

Lexaria Bioscience (NASDAQ: LEXX) has, since its inception, remained committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs. Through its patented DehydraTECH(TM) drug delivery technology that began development in 2014, the company is offering potential solutions for conditions including, but not limited to hypertension, smoking cessation, anti-viral treatments, and other drug classes. In what has marked a landmark achievement for Lexaria, its DehydraTECH technology proved effective for sildenafil delivery in an animal study conducted on lab rats. In addition, the study demonstrated that this technology offered improved treatment of erectile dysfunction, a condition that, according to estimates, will affect about 322 million men worldwide by 2025 (https://ibn.fm/85fJS). When compared to the most common sildenafil product- Viagra, Lexaria’s alternative proved to be more effective, with a delivery of 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation. For reference, Viagra is only moderately bioavailable orally at about 40%, with most people citing its slowness to act as a primary complaint. Lexaria has also made incredible developments with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD. Given the success of previous studies, the company also announced plans for more trials over the year 2022. “During 2021, we completed research & development (‘R&D’) and validating work equal to or greater than all the combined amount previously completed since 2018!” noted Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria. “We have conducted studies across broad areas of interest but also concentrated in specific areas where we have had supportive data,” he added (https://ibn.fm/GH95e). For 2022, the company is focusing on DehydraTECH-processed-CBD for potential heart disease and hypertension treatment. Mr. Bunka also noted that from April (or sooner), the company should kick off what it terms as its largest-ever hypertension study. “If this study is successful, we feel strongly that it will be highly supportive of our IND filing plan, and we will have a clear path toward designing of Phase 1 and even potentially Phase II FDA-registered clinical studies thereunder. Assuming there are no major delays either in study execution or evaluation, we expect full results from this study sometime in Q3, 2022,” noted Mr. Bunka. These strides stamp Lexaria’s position as a global innovator in drug delivery platforms. But, more importantly, they seek to create value for shareholders while also positioning the company for growth as time progresses. Lexaria looks to capitalize on this growth and is, therefore, investing heavily into its R&D to introduce new treatments and receive regulatory approval for existing ones. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

Lifescience, biotech, medical device, and healthcare professionals, industry influencers, and health insurance companies are invited to attend DGE’s 8th Advancing Women’s Leadership Skills & Opportunities Conference being held on March 28-30, 2022, as a live streaming event. This conference focuses on shaping and building the career of women entrepreneurs in the health and pharma sectors. The event is hosted by Dynamic Global Events (“DGE”), a Life Science leader in organizing b2b events. The global event company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries.  Successful business strategies and optimum planning are pivotal for inspiring women professionals who are looking to advance in their career paths. It is the need of the hour as healthcare and pharma companies as more women professionals are becoming a part of the healthcare workplace. This move is particularly important in the evolving medical scenario where women have phenomenal leadership skills that can take them to the top positions within their organizations. The 8th Advancing Women’s conference by DGE will be attended by industry stalwarts, solution providers, venture capitalists and government entities who will discuss the challenges and hurdles that came in their way of reaching the top. They will share insights into their professional journey. Aspiring candidates and new businesses can seek guidance and design business strategies for future expansion. The DGE event will feature such inspiring success stories from top women leaders that will inspire the new genre of industry heads. The Conference focuses on educating, inspiring, and shaping women careers in leadership roles to bridge the gender disparity in the health/pharma industry. The event will kickstart with an introduction from the Chairperson Hani Houshyar, VP, Head of Pipeline Product Development & Commercialization. Participants can learn how to advocate themselves and understand the tactics of self-confidence at the fireside chat events. New women entrepreneurs or those who have been in this field for a while will learn important tips of turning around obstacles to launch pads for success. The virtual event platform will serve as a wonderful avenue for women medical and healthcare professionals for learning to manage their roles as a leader, face work challenges and get maximum productive output. Influential speakers at the DGE conference will share insights showcasing their leadership skills and professional achievements in the medical industry. For more details, please visit https://ibn.fm/tptAf.